Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy - Enduring

Neuroblastoma is one of the most common types of pediatric solid tumors and yet targeted immunotherapy of this disease is very limited. Pediatric oncologists need to stay abreast on advances in neuroblastoma management in order to apply the current state of the field to pediatric malignancies where appropriate.  It is therefore, imperative that they hear from a leading expert in the field, to understand how the results of molecular evaluations alter management. Genomic advances have altered the landscape of neuroblastoma management.  As more data is acquired, risk stratification and therapy continues to evolve.

Target Audience

City of Hope Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, City of Hope staff and research teams.

Learning Objectives

  • Integrate advances in neuroblastoma management into current practices.
  • Discuss applicability of these advances to management of other pediatric malignancies.
  • Identify risk stratification by molecular evaluations in pediatric neuroblastoma.

Additional Information

AttachmentSize
PDF icon AB 1195 Bibliography163.35 KB
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
08/16/2021
Activity expires: 
08/16/2022
Part of: 
Pediatric Grand Rounds | Recordings
Internet
United States

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.

Presenter: Dr. Araz Marachelian has indicated that is receives Grant/Research Support from Pfizer and United Therapeutics; Consultant for United Therapeutics and YmAbs Therapeutics. 

City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.

This activity will include a discussion of the off-label or investigational use of isotretinoin, cyclophosphamide, topotecan, dinutuximab, dinutiximab-Beta, accutane, cisplatin, metaiodobenzylguanidine (MIBG), irinotecan-temozolomide, temsirolimus, vincristine, irinotecan, omburtamab, alisertib, crizotinib, lorlatinib, and vorinostat.

The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.

Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy - Enduring has received no commercial support.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.

You must be logged in to access this Enduring. 

If you are a New User, please create an account first, by clicking on "Register". 

Once Logged in: 

Click on "Start Activity" to access the educational content for this Enduring activity.

Required Hardware/software

Current version of Edge, Firefox, Safari, or Chrome.